Seraseq® Clinical Genomics Products: New and Coming Soon

LGC Clinical Diagnostics is the market leader in genomics reference materials with an innovative portfolio that continues to grow! This is a list of recently launched products and ones planned for release in 2026-2027.

Liquid Biopsy

ctDNA v4 Reference Materials - Available Now!

The same 93 variants and VAFs as present in ctDNA v4 Mutation Mix in extractable plasma format for a full-process reference material.

cfRNA Fusion Mix - Available Now!

Seraseq cfRNA Fusion Mix is a first-to-market multiplexed pan-cancer RNA reference material containing 19 RNA fusion transcripts sized to mimic cell-free RNA fragments.

ctDNA Methylated Disease State(s) - **Coming in 2027**

ctDNA reference materials retaining base pair information, fragment size profiles and CpG methylation patterns of patient ctDNA samples. Based on our patented NIPT amplification processes expanded to include preservation of methylation signals, available for early access evaluation in 2026.

Solid Tumor & Myeloid Tumor

Tumor Mutation DNA Mix v3 - Available Now!

A major update of the flagship Solid Tumor v2 AF10, AF7 and Tri-Level products with 100+ solid tumor variants including CNVs for better compatibility with comprehensive genomic profiling assays.

CNV Copy Loss DNA Mix - Available Now!

Derived from a tumor cell line with 7 gene copy losses, including MTAP, TP53, and PTEN. Available in genomic DNA format, suitable for all NGS methods detecting copy loss including long-read sequencing.

Endometrial Cancer DNA Mix - Available Now!

Genomic DNA reference material containing 32 variants relevant to the diagnosis and treatment of endometrial cancer across all molecular subtypes, including genes such as POLE, TP53 and PIK3CA.

Extracted FFPE RNA Fusion v4 Mix - **Available Summer 2026**

RNA reference material with 18 solid tumor fusion transcripts, and RNA compromised by extraction from FFPE curls. A full-process control without the need for extraction and with predictable RNA yield.

Myeloid DNA v2 & Fusion RNA v2 - **Available Late 2026**

An update to the best-selling Myeloid DNA and RNA products with nearly double the variant content compared to the current on market offerings.

Inherited Diseases & Reproductive Health

Twin cfDNA for NIPT - **Available Now!**

Reference materials for the validation of NIPT for twin pregnancies. Derived from pregnant donors with 22q11 microdeletion or euploid twin gestations, closely mimicking patient cell free DNA.

Antepartum SMA cfDNA for NIPT - **Available now!**

Reference materials supporting Spinal Muscular Atrophy (SMA) screening via Non-Invasive Prenatal Testing (NIPT), perfect for fetal fraction Limit of detection studies.

Lyophilized NIPT Reference Materials - **Available Now!**

Full-process NIPT reference materials supplied lyophilized to be reconstituted with water and processed like patient samples. Stable at room temperature for convenient storage and shipping.

Newborn Duo Reference Materials - **Available Now!**

Reference materials consisting of genomic DNA isolated from maternal and fetal cell lines collected from either a Hemophilia B carrier pregnant patient with a non-affected fetus or from a healthy pregnant patient carrying a fetus with SMA. Qualified by long-read sequencing.

Discordant Twins cfDNA for NIPT - **Available Fall 2026**

NIPT reference material derived from a rare twin pregnancy with one male euploid fetus and one female trisomy 21 fetus, perfectly mimicking a complex and rare twin clinical case.

Pharmacogenomics

DPYD - **Available Now!**

Broad reference material including 39 variants impacting the function of the DPYD gene. Pan-ethnic variants selected based on global guidelines (AMP, CPIC, EMA, DPWG).

PGx - **Available Now!**

Comprehensive pharmacogenomics reference material including 79 clinically relevant variants across 13 pharmacogenes, following AMP Tier 1 and Tier 2 recommendations; to predict drug response and adverse drug reactions.

PGx CYP2D6 - **Available Winter 2026 / Early 2027**

This product in development will contain complex CYP2D6 variants optimized for long-read sequencing methods.